EHA 2022 | Insights into a study evaluating tagraxofusp for the treatment of BPDCN
Uwe Platzbecker
• 21 Jun 2022
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, shares some insights into a study investigating the use of tagraxofusp, a recently approved CD123-targeted therapy, for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Receiving grant support, paid to GWT-TUD, from Amgen, lecture fees, grant support, paid to the University of Leipzig, fees for serving on a steering committee, consulting fees, and travel support from Celgene, grant support, paid to GWT-TUD, from Janssen Biotech, grant support, paid to University Dresden, from Merck and Novartis, and lecture fees from Novartis.
